Losartan Recalled Expanded: Ten Lots Recalled
On January 3, 2019, the FDA issued yet another recall of Losartan Potassium tablets. The first recall was issued November 9, 2018 and involved 2 lots. Now, Torrent Pharmaceuticals Limited is recalling a total of 10 lots due to the unexpected impurity N-nitrosodiethylamine (NDEA) found in the drug.
Losartan is a medication used to treat hypertension. It was recalled following the recall of similar drugs Valsartan and Irbesartan for containing NDEA and N-nitrosodimethylamine (NDMA). These substances are classified as probable human carcinogens by the Environmental Protection Agency. Exposure to NDEA can cause:
- Liver Cancer
- Stomach Cancer
- Colon Cancer
- Intestinal Cancer
- Prostate Cancer (Must be diagnosed before age 60)
- Lower Esophageal Cancer
- Non-Hodgkin Lymphoma
- Multiple Myeloma
- Pancreatic Cancer
The products subject to recall can be found on the FDA’s website, which lists the product description, batch/lot number, and expiration date.
If you or a loved one was diagnosed with liver cancer, stomach cancer, colorectal cancer, intestinal cancer, esophageal cancer, prostate cancer, pancreatic cancer, non-hodgkin’s lymphoma, leukemia, or multiple myeloma after taking Losartan, please contact us. We have over 30 years of experience handling dangerous drug cases. At GoldenbergLaw, we deliver the Gold standard advocacy you deserve.